Acumen Sciences

Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing targeted therapies for Alzheimer’s disease. The company’s lead candidate, sabirnetug (ACU193), is a humanized monoclonal antibody designed to selectively target and neutralize soluble amyloid-beta oligomers (AβOs), which are widely considered a primary toxic form of amyloid-beta. Unlike other amyloid-targeting therapies that focus on plaques, Acumen’s approach aims to address the early triggers of synaptic dysfunction and neurodegeneration. The company is currently advancing sabirnetug through Phase 2 clinical trials to evaluate its safety and efficacy in patients with early Alzheimer's disease. Acumen was founded on pioneering research into the "oligomer hypothesis" and continues to explore the role of AβOs in neurodegenerative progression.